The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study: Tofacitinib improves the clinical signs of psoriasis
Abstract
BACKGROUND: Tofacitinib is a novel, oral Janus kinase inhibitor under investigation as a potential treatment for plaque psoriasis. OBJECTIVES: This Phase 2b, 12-week, dose-ranging study (A3921047, NCT00678210) aimed to characterize the exposure-response, efficacy and safety of tofacitinib vs. placebo in patients with moderate-to-severe chronic plaque psoriasis. METHODS: One hundred and ninety-seven patients were randomized. The primary endpoint was the proportion of patients achieving a ≥ 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score at week 12. RESULTS: At week 12, PASI 75 response rates were significantly higher for all tofacitinib twice-daily groups: 25·0% (2 mg; P < 0·001), 40·8% (5 mg; P < 0·0001) and 66·7% (15 mg; P < 0·0001), compared with placebo (2·0%). Significant increases in the proportion of PASI 75 responses were seen by week 4 and were maintained at week 12. Exposure-response over the 0-15 mg tofacitinib twice-daily dose range was successfully characterized. PASI 50, PASI 90 and Physician's Global Assessment response rates were also higher for tofacitinib vs. placebo. The most frequently reported adverse events (AEs) were infections and infestations: 22·4% (2 mg twice daily), 20·4% (5 mg twice daily), 36·7% (15 mg twice daily) and 32·0% (placebo). Discontinuations due to AEs were 6·0%, 2·0%, 4·1% and 6·1% of patients in the placebo, and 2, 5 and 15 mg twice-daily tofacitinib groups, respectively. Dose-dependent increases from baseline in mean serum high-density lipoprotein, low-density lipoprotein and total cholesterol, and decreases in haemoglobin and neutrophils were observed. CONCLUSION: Short-term treatment with oral tofacitinib results in significant clinical improvement in patients with moderate-to-severe plaque psoriasis and is generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control study
Gisondi, P., Tessari, G., Conti, A., Piaserico, S., Schianchi, S., Peserico, A., Giannetti, A., & Girolomoni, G. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07986.x · Cited by 675
Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-41 · Cited by 461
Li, D.-Q., Chen, Z., Song, X. J., Luo, L., & Pflugfelder, S. C. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0299 · Cited by 392
Fleischmann, R., Cutolo, M., Genovese, M. C., Lee, E. B., Kanik, K. S., Sadis, S., Connell, C. A., Gruben, D., Krishnaswami, S., Wallenstein, G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33383 · Cited by 376
Self-citationKremer, J. M., Cohen, S., Wilkinson, B. E., Connell, C. A., French, J. L., Gomez‐Reino, J., Gruben, D., Kanik, K. S., Krishnaswami, S., Pascual‐Ramos, V., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33419 · Cited by 344
Self-citationThe prevalence of psoriasis in African Americans: Results from a population-based study
Gelfand, J. M., Stern, R. S., Nijsten, T. E. C., Feldman, S. R., Thomas, J., Kist, J., Rolstad, T., & Margolis, D. J. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.07.045 · Cited by 310
New Insights in the Immunologic Basis of Psoriasis
Nograles, K. E., Davidovici, B., & Krueger, J. G. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.03.001 · Cited by 196
Naldi, L., & Griffiths, C. E. M. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06563.x · Cited by 183
Consensus Guidelines for the Management of Plaque Psoriasis
Hsu, S. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2011.1410 · Cited by 161
Boy, M. G., Wang, C., Wilkinson, B. E., Chow, V. F.-S., Clucas, A., Krueger, J. G., Gaweco, A. S., Zwillich, S. H., Changelian, P. S., & Chan, G. L. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.25 · Cited by 142
Age at onset and different types of psoriasis
Swanbeck, G., Inerot, A., Martinsson, T., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb02753.x · Cited by 140
Targeting the Jak/STAT pathway for immunosuppression
O’Shea, J. J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.028290 · Cited by 103
Papp, K. A., Bissonnette, R., Rosoph, L. A., Wasel, N. R., Lynde, C. W., Searles, G. E., Shear, N., Huizinga, R. B., & Maksymowych, W. P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60593-0 · Cited by 95
Self-citationEvaluation and Management of Psoriasis: An Internist's Guide
Levine, D. E., & Gottlieb, A. B. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.08.003 · Cited by 72
JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice
Chang, B. Y., Zhao, F., He, X., Ren, H., Braselmann, S., Taylor, V., Wicks, J. R., Payan, D. G., Grossbard, E. B., Pine, P. R., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804063 · Cited by 65
Good and bad memories following rituximab therapy
Clair, E. W. S. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25039 · Cited by 51
Cited by
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Clark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
Metadata
- Authors
- Papp, K. A., Menter, A., Strober, B., Langley, R. G., Buonanno, M., Wolk, R., Gupta, P., Krishnaswami, S., Tan, H., & Harness, J. A.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-27
- Volume
- 167
- Issue
- 3
- Pages
- 668-677
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W2167305078
- Cited by
- 338
- References
- 18
- FWCI
- 15.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.